Table 4. Comparison of pre- and post-treatment variables in the CHC patients with SVR stratified by baseline IR.
SVR (G1 and G2) with baseline IR(n = 63) | Paired t-testP values | SVR (G1 and G2) without baseline IR(n = 132) | Paired t-testP values | |||
Pre- treatmentvalue | Post-treatmentvalue | Pre- treatmentvalue | Post-treatmentvalue | |||
Male (%) | 37 (62.7%) | 68 (60.1%) | ||||
Age (yr) | 54.5+/−12.6 | 52.3+/−12.5 | ||||
BMI | 25.7+/−3.6 | 25.5+/−3.5 | 0.111 | 23.5+/−3.0 | 23.3+/−2.9 | 0.201 |
IL-28B rs12979860CC/CT+TT, n(CC%) | 59/4(93.6%) | 121/7(91.66%) | ||||
TG(mg/dL) | 106.1+/−45.0 | 130.6+/−85.1 | 0.004* | 96.0+/−44.7 | 113.1+/−65.5 | 0.003* |
TC(mg/dL) | 166. 0+/−29.7 | 182.4+/−40.9 | <0.001* | 168.3+/−32.8 | 184.1+/−36.1 | <0.001* |
HDL(mg/dL) | 43.8+/−13.2 | 47.0+/−11.6 | 0.019* | 51.2+/−13.6 | 52.4+/−14.7 | 0.188 |
LDL(mg/dL) | 100.5+/−25.5 | 112.3+/−35.9 | 0.002* | 100.3+/−28.6 | 112.9+/−31.4 | <0.001* |
TG/HDL | 2.7+/−1.8 | 3.2+/−3.0 | 0.135 | 2.0+/−1.2 | 2.4+/−2.2 | 0.022* |
Apo AI(g/L) | 1.28+/−0.26 | 1.37+/−0.23 | 0.012* | 1.45+/−0.26 | 1.48+/−0.26 | 0.111 |
Apo B (g/L) | 0.84+/−0.17 | 0.87+/−0.20 | 0.274 | 0.80+/−0.19 | 0.88+/−0.23 | <0.001* |
Sugar (mg/dL) | 116.3+/−44.6 | 120.1+/−76.5 | 0.601 | 90.2+/−8.9 | 95.0+/−15.7 | 0.001* |
Insulin (µIU/mL) | 19.7+/−21.9 | 16.8+/−27.0 | 0.223 | 6.9+/−2.8 | 8.0+/−4.6 | 0.016* |
C-peptide (ng/mL) | 3.9+/−2.5 | 3.0+/−1.5 | 0.019* | 1.9+/−1.0 | 2.2+/−1.8 | 0.095 |
Hb-A1c (%; mmol/mol) | 6.2+/−1.3;44+/−14 | 5.9+/−0.8;41+/−9 | 0.047* | 5.6+/−0.4;37.5+/−4.5 | 5.6+/−0.5;37.5+/−5.5 | 0.546 |
HOMA-IR | 6.2+/−11.7 | 4.6+/−6.7 | 0.04* | 1.5+/−0.5 | 1.9+/−1.2 | 0.002* |
*p<0.05.